According to the CDC, stroke is the fifth leading cause of death in the US, killing about 140,000 people each year. More than 795,000 people in the US have a stroke each year, adding up to an estimated $34 billion in health care services, medicines to treat stroke and missed days of work. Detecting signs of a potential stroke early can be critically important to preventing long term disability or death. Patients who arrive at the emergency room within three hours of their first symptoms often have less disability than those who received delayed care.
The use of artificial intelligence (AI) is undoubtedly on the rise in healthcare. From fledging medtech companies to established giants like Watson IBM—many firms are riding the current AI wave. Not only are companies embracing technology, but so is FDA.
Viz.AI Contact software that provides artificial intelligence-assisted stroke detection for CT scans and automatically notifies neurovascular specialists by text message got U.S. marketing approval from the FDA, the agency announced.
February 13, 2018 -- In a move that blazes a regulatory trail for developers of imaging artificial intelligence (AI) software, the U.S. Food and Drug Administration (FDA) has given its blessing to Viz.ai for Contact, an AI-based application that analyzes CT images and notifies providers that a patient might be having a stroke